Alzheimer’s Drug Makes a Comeback

The pharma company claims a previous decision to discontinue research into the drug was based on incomplete Phase 3 trial data and new analysis has revealed significant success
The pharma company claims a previous decision to discontinue research into the drug was based on incomplete Phase 3 trial data and new analysis has revealed significant success

In a stunningly unusual turn of events a new Alzheimer’s drug, previously declared a failure back in March, has been resurrected with the pharmaceutical company behind the treatment suggesting the earlier decision to discontinue the research was premature and based on incorrect data analysis. read more